drugset / Trial / NCT06188520
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
Timeline
- Start
- 2023-12-05
- Primary completion
- 2027-08-04
- Completion
- 2027-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD8421 | Unknown | — | — |
| Subject | Abemaciclib | Small molecule | — | — |
| Subject | Camizestrant | Other / unclassified | — | — |
| Subject | Palbociclib | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | — |